Expertise in
13
conditions

Ravi Savarirayan

Flemington Road, 
Parkville, VIC, AU 
Expertise in
13
conditions
Flemington Road, 
Parkville, VIC, AU 

Overview

Ravi Savarirayan practices practicing medicine in Parkville, Australia.

Mr. Savarirayan is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Achondroplasia, Acanthosis Nigricans, Chondrodystrophy, and X-Linked Spondyloepiphyseal Dysplasia Tarda.

He is actively involved in clinical research, co-authoring 120 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Flemington Road, Parkville, VIC 3052, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Prospective Clinical Assessment Study in Children With Achondroplasia: The PROPEL Trial
Prospective Clinical Assessment Study in Children With Achondroplasia: The PROPEL Trial
Enrollment Status: Completed
Publish Date: April 03, 2026
Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL OLE
Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL OLE
Enrollment Status: Enrolling_by_invitation
Publish Date: October 31, 2025
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 2
Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2
Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2
Enrollment Status: Completed
Publish Date: October 22, 2025
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 2
View 2 Less Clinical Trials

120 Total Publications

Pathways to Facilitate Early Recognition and Diagnosis of Hypochondroplasia.
Pathways to Facilitate Early Recognition and Diagnosis of Hypochondroplasia.
Journal: Advances in therapy
Published: December 24, 2025

Frequently Asked Questions about Ravi Savarirayan

Is Ravi Savarirayan a top-rated expert for Achondroplasia?

MediFind is an objective health platform that identifies experts based on real-world data. Ravi Savarirayan is classified as an Elite expert for Achondroplasia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ravi Savarirayan participate in research or clinical trials?

Yes. Ravi Savarirayan has published 120 articles and abstracts on conditions like Achondroplasia. You can view a list of Ravi Savarirayan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Savarirayan's expertise for a condition
ConditionClose
View All 44 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile